Bioquell Regulatory News (BQE)

29 June, 2011

BIOQUELL PLC

Award of a £4 million contract by DEFTECH of Malaysia for the supply of specialist chemical, biological, radiological and nuclear ("CBRN") filtration systems for military vehicles

Bioquell PLC (LSE: BQE) ("Bioquell") - provider of specialist low temperature, residue-free bio-decontamination and filtration technologies to the healthcare, life sciences and defence sectors - announces that DRB-HICOM Defence Technologies Sdn Bhd ("DEFTECH"), a substantial Malaysian defence corporation, has awarded Bioquell a contract worth approximately £4 million for the supply of specialist CBRN filtration systems for incorporation into military vehicles being manufactured by DEFTECH in Malaysia. Bioquell will start to supply these CBRN systems at the beginning of 2013 and the contract is scheduled to run for five years.

Commenting on this Malaysian contract award, Nick Adams, Group Chief Executive of Bioquell PLC, said:

"We are extremely pleased to have been awarded this £4 million CBRN filtration systems contract from a leading Malaysian defence group."

"This contract award - which helps build our defence order book - underscores Bioquell's increasing success in the Asia Pacific region."

- Ends -

Enquiries:

Bioquell PLC 01264 835 900

Nick Adams Group Chief Executive

Mark Bodeker Chief Operating Officer / Finance Director

Notes to editors:

§ Bioquell is a UK-headquartered, international technology company with two divisions:

o Bio-decontamination which sells specialist bio-decontamination products and services into the Healthcare, Life Sciences and Defence sectors, with most of its revenues generated from overseas customers; and

o TRaC which provides UK corporates with specialist Testing, Regulatory and Compliance services - many of which are required by national and international regulations.

§ Bioquell's gas phase bio-decontamination technology uses hydrogen peroxide vapour ("HPV") - which is highly efficacious at eradicating micro-organisms such as bacteria, viruses and fungi at room temperature - and is subsequently broken down using specialist catalysts to water vapour and oxygen at the end of the bio-decontamination process.

§ Bioquell's specialist filtration technology including peroxide catalysis and chemical, biological, radiological and nuclear ("CBRN") filtration systems used principally in the defence sector is highly complementary to the defence application for its HPV technology which is used to decontaminate biological and chemical warfare agents.

§ Bioquell's bio-decontamination technology:

o is used by bio-pharmaceutical, biologics, biotechnology and research institutions to provide sterile equipment and/or sterile working environments - which is of particular interest to organisations working with biologically-derived drugs;

o is used to eradicate drug resistant organisms associated with Hospital Acquired Infection as well as problematic viruses from the hospital environment. Independent scientific research has demonstrated that 'bioquelling' hospital equipment and facilities reduces the rates of hospital acquired infection;

o was selected by the United States Department of Defense for the JSSED programme to decontaminate sensitive equipment against biological and chemical warfare agents;

o benefits from a number of granted or pending patent filings in the UK and internationally; and

o is used in other sectors where bioburden can create significant problems including, for example, the food industry.

§ Bioquell currently has overseas operations in the USA, France, Ireland, Singapore and China.

§ TRaC sells its specialist testing services to the product development and engineering departments of a broad range of companies and organisations, principally based in the UK, with a particular focus on the aerospace, military and telecoms sectors.